Synairgen’s inhaled drug cuts chances of COVID-19 progressing

An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease.

Southampton-based Synairgen said in a preliminary trial readout that the company’s SNG001 – an inhaled formulation of interferon beta – reduced risk of progression from “requiring oxygen” to ventilation by 79%.